Tag: BiTE

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Immunotherapy Web Featured Images 109

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are are a few highlights from this week.

Read more
Onclive27

Teclistamab Shows Continued Promise in R/R MM: Updated phase 1 results

Teclistamab demonstrated encouraging clinical activity, along with a tolerable safety profile, in patients with relapsed/refractory multiple myeloma.

Visit website
Immunotherapy Web Featured Images 109

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are are a few highlights from this week.

Read more
Immunotherapy Web Featured Images 1

Bispecific Antibodies Could Be the Next Big Advance in Oncology

  Mar 11 2021 Tagged mAbs, BiTE

Human monoclonal antibody therapies are among the fastest growing categories in the cancer pipeline, with more than 570 agents in clinical development. Now, a new type of antibody-based therapy may overcome the limitations of monoclonal antibodies, and it has the potential to disrupt the current treatment paradigm in oncology.

Visit website
Immunotherapy Web Featured Images

The Growing Role of Monoclonal Antibodies in Relapsed/Refractory Follicular Lymp...

Although it is too soon to tell whether the addition of a CD20-directed antibody to novel agents in relapsed/refractory follicular lymphoma should become standard practice, it is clear that immunotherapy could represent the next paradigm shift.

Visit website
Immunotherapy Web Featured Images 2

Immunotherapy Is on the Cusp of Major Breakthroughs in Multiple Myeloma

Just a decade ago, immune therapy for multiple myeloma barely existed as an idea. Since then, immune therapy has evolved rapidly and the field is on the verge of major improvements in outcomes.

Visit website
Onclive17

Relapsed/Refractory DLBCL Undergoes Rapid Evolution With CAR T-Cell Therapy, ADC...

High-dose chemotherapy and transplant remains the second-line standard of care for the majority of patients with relapsed/refractory diffuse large B-cell lymphoma; however, CAR T-cell therapy and other novel agents, which have transformed the third-line setting, may offer alternative and more personalized second-line options in the coming years.

Visit website
Immunotherapy Web Featured Images 120

Bispecific Antibodies Propel the Relapsed/Refractory Myeloma Paradigm Further Ah...

  Mar 03 2021 Tagged mAbs, BiTE, MM

Timothy M. Schmidt, MD, discusses the integration and utility of bispecific antibodies in relapsed/refractory multiple myeloma, as well as some of the most promising agents in clinical development.

Visit website
onclive5

Monoclonal Antibodies Prove to Be Novel Therapeutics for Myeloma

  Feb 24 2021 Tagged Abs, CAR-T, BiTE, ADC, MM

Novel drugs have especially improved the treatment options for relapsed myeloma, with some agents now also being used as frontline therapy. As a result, outcomes for patients with newly diagnosed and relapsed disease continue to improve with prolongation of median survival to greater than 7 years from diagnosis.

Visit website
Onclive14

Looking to Novel Immunotherapeutics in Relapsed/Refractory Multiple Myeloma

Marc J. Braunstein, MD, PhD, discusses the evolution and promise of immunotherapeutics in multiple myeloma.

Visit website